We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To demonstrate value in the age of personalized medicine, drugmakers must adjust their marketing campaigns around patients’ real-world experiences, a new PricewaterhouseCoopers (PwC) report says. Read More
Aegerion Pharmaceuticals CEO Marc Beer’s televised comments about the company’s heart drug Juxtapid have drawn a warning letter from the FDA for failing to mention drug risks and promoting an off-label use. Read More